Stay updated on Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial

Sign up to get notified when there's something new on the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The site’s footer revision identifier changed from v3.7.1 to v3.7.2. The page still displays a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-18T14:35:19.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov revision label in the footer changes from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-11T13:45:53.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    The 403 Forbidden error view was replaced with the actual study details page for NCT02982720, enabling access to the study information and navigation.
    Difference
    0.5%
    Check dated 2026-09-27T17:35:21.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study details with a standard error page and a minimal site footer. This indicates restricted access to the ClinicalTrials.gov study record for NCT02982720.
    Difference
    19%
    Check dated 2026-09-20T10:32:02.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The page now displays a new Revision: v3.6.6 label, indicating a minor build/version update.
    Difference
    0.1%
    Check dated 2026-08-29T23:46:25.000Z thumbnail image
  7. Check
    77 days ago
    Change Detected
    Summary
    The page's revision tag was updated from v3.6.4 to v3.6.5, reflecting a backend/page update.
    Difference
    0.1%
    Check dated 2026-08-08T20:27:16.000Z thumbnail image

Stay in the know with updates to Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page.